U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

                For the quarterly period ended September 30, 1999

                                       OR

[_]  TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR  15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934

     For the transition period from ____________ to ________

     Commission File Number 000-27353


                            SELECT THERAPEUTICS, INC.
        (Exact name of small business issuer as specified in its charter)

             Delaware                                     98-0169105
 (State or other jurisdiction of                       (I.R.S. Employer
  incorporation or organization)                      Identification No.)

124 Mt. Auburn St., Suite 200 North, Cambridge, MA         02138
     (Address of principal executive offices)           (Zip Code)

                                 (617) 520-6693
                (Issuer's telephone number, including area code)

                                       N/A
             (Former name, former address and former fiscal year, if
                 changed since last report)

Check  whether the Issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days.   Yes |_|  No [X]

The aggregate  number of shares  outstanding of the Issuer's  Common Stock,  its
sole class of common equity, was 6,101,358 as of January 7, 2000.

Transitional Small Business Issuer Disclosure Format: Yes [_] No [X]


                    Page 1 of 16; Exhibit Index is on Page 14
<PAGE>


                    Consolidated Financial Statements
                    (Stated in U.S. dollars)

                    SELECT THERAPEUTICS INC.
                    (A DEVELOPMENT STAGE ENTERPRISE)

                    Three months ended September 30, 1999 and 1998
                    (Unaudited)

                                       2

<PAGE>


SELECT THERAPEUTICS INC.
(A DEVELOPMENT STAGE ENTERPRISE)

Consolidated Balance Sheets
(Stated in U.S. dollars)
(Unaudited)

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------
                                                      September 30,       June 30,
                                                               1999           1999
                                                                         (audited)
----------------------------------------------------------------------------------
<S>                                                     <C>            <C>
Assets

Cash and cash equivalents                               $    44,980    $   120,881
Restricted cash                                              72,000         72,000
Accounts receivable                                              --          7,380
Inventory                                                    68,104         32,130
Prepaid expenses and other assets                            18,380         21,740
Property, plant and equipment                               128,542        104,547
Intangible assets                                           835,644        900,581

----------------------------------------------------------------------------------
                                                        $ 1,167,650    $ 1,259,259
==================================================================================

Liabilities and Shareholders' Equity

Liabilities:
     Accounts payable                                   $   240,677    $    43,309
     Accrued liabilities                                    684,285        655,798
----------------------------------------------------------------------------------
                                                            924,962        699,107

Shareholders' equity:
     Capital stock:
         Authorized:
              1,000,000 preferred shares
              10,000,000 common shares,
                $0.001 par value
         Issued:
              6,101,358 common shares
                (June 30, 1999 - 5,634,094)                   5,720          5,634
     Contributed surplus                                  5,355,034      5,140,120
     Deficit accumulated during the development stage    (5,118,066)    (4,585,602)
----------------------------------------------------------------------------------
                                                            242,688        560,152

----------------------------------------------------------------------------------
                                                        $ 1,167,650    $ 1,259,259
==================================================================================
</TABLE>


See accompanying note to consolidated financial statements.


                                       3
<PAGE>


SELECT THERAPEUTICS INC.
(A DEVELOPMENT STAGE ENTERPRISE)

Consolidated Statements of Operations
(Stated in U.S. dollars)

Three months ended September 30, 1999 and 1998
(Unaudited)

-------------------------------------------------------------------------------
                                                         1999              1998
-------------------------------------------------------------------------------

Revenue                                           $    93,125       $        --
Cost of revenue                                        13,711                --
-------------------------------------------------------------------------------
                                                       79,414                --

Interest income                                           506            14,908

Research and development                              121,669           228,038
Selling, general and administration                   415,820           316,342
Depreciation                                            9,958                --
Amortization                                           64,937                --
-------------------------------------------------------------------------------
                                                      612,384           544,380

-------------------------------------------------------------------------------
Loss for the period                               $  (532,464)      $  (529,472)
===============================================================================

Loss per share                                    $     (0.09)      $     (0.13)

Weighted average number of shares                   5,819,354         4,164,534

--------------------------------------------------------------------------------

Consolidated Statements of Changes in Shareholders' Equity
(Stated in U.S. dollars)

Three months ended September 30, 1999
(Unaudited)

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------
                                                                             Deficit
                                                                         accumulated
                                                                          during the
                                      Common shares       Contributed    development
                                   Shares        Amount       surplus          stage         Total
--------------------------------------------------------------------------------------------------
<S>                             <C>         <C>           <C>           <C>            <C>
Balance, June 30, 1998          4,981,313   $     4,981   $ 3,176,046   $(2,118,274)   $ 1,062,753

Issue of common shares            652,781           653     1,964,074            --      1,964,727

Loss for the period                    --            --            --    (2,467,328)    (2,467,328)
--------------------------------------------------------------------------------------------------

Balance, June 30, 1999          5,634,094         5,634     5,140,120    (4,585,602)       560,152

Issue of common shares            467,264            86       214,914            --        215,000

Loss for the period                    --            --            --      (532,464)      (532,464)

--------------------------------------------------------------------------------------------------
Balance, September 30, 1999     6,101,358   $     5,720   $ 5,355,034   $(5,118,066)   $   242,688
==================================================================================================
</TABLE>


See accompanying note to consolidated financial statements.


                                       4
<PAGE>

SELECT THERAPEUTICS INC.
(A DEVELOPMENT STAGE ENTERPRISE)

Consolidated Statements of Cash Flows
(Stated in U.S. dollars)

Three months ended September 30, 1999 and 1998
(Unaudited)

--------------------------------------------------------------------------------
                                                            1999           1998
-------------------------------------------------------------------------------

Cash provided by (used in):

Operating activities:
     Loss for the period                             $  (532,464)   $  (529,472)
     Items not involving cash:
         Depreciation                                      9,958             --
         Amortization                                     64,937             --
         Issue of common shares for services              90,000             --
     Changes in non-cash operating working capital:
         Accounts receivable                               7,380             --
         Inventory                                       (35,974)            --
         Prepaid expenses and other assets                 3,360             --
         Accounts payable                                197,368        (16,720)
         Accrued liabilities                              28,487        (33,180)
-------------------------------------------------------------------------------
                                                        (166,948)      (579,372)

Financing activities:
     Increase in loans to Sierra Diagnostics, Inc.            --       (105,000)
     Proceeds from issuance of common shares             125,000             --
-------------------------------------------------------------------------------
                                                         125,000       (105,000)

Investing activities:
     Additions to property, plant and equipment          (33,953)            --
-------------------------------------------------------------------------------

Decrease in cash                                         (75,901)      (684,372)

Cash and cash equivalents, beginning of period           120,881      2,070,705

-------------------------------------------------------------------------------
Cash and cash equivalents, end of period             $    44,980    $ 1,386,333
===============================================================================

Supplementary disclosure:
     Non-cash financing and investing activities:
         Issue of common shares for services         $    90,000    $        --

-------------------------------------------------------------------------------


See accompanying note to consolidated financial statements.


                                       5
<PAGE>

SELECT THERAPEUTICS INC.
(A DEVELOPMENT STAGE ENTERPRISE)

Note to Consolidated Financial Statements
(Stated in U.S. dollars)

Three months ended September 30, 1999 and 1998
(Unaudited)

--------------------------------------------------------------------------------


Basis of presentation:


In the opinion of management, the unaudited consolidated financial statements of
Select Therapeutics Inc. (the "Company") included herein have been prepared on a
consistent  basis  with  the  June  30,  1999  audited  consolidated   financial
statements and include all material adjustments,  consisting of normal recurring
adjustments,  necessary to fairly  present the  information  set forth  therein.
These interim  financial  statements should be read in conjunction with the June
30, 1999  audited  consolidated  financial  statements  and notes  thereto.  The
Company's  results of  operations  for the first fiscal  quarter of 1999 are not
necessarily indicative of future operating results.


The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect the amounts  reported in the financial  statements.  Actual results could
differ materially from those estimates.


                                       6
<PAGE>


ITEM 2.   MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF  FINANCIAL  CONDITION  AND
          RESULTS OF OPERATIONS

     This  Management's  Discussion  and  Analysis of  Financial  Condition  and
Results of Operations  contains  forward-looking  statements which involve risks
and  uncertainties.   Select  Therapeutics  Inc.'s  actual  results  may  differ
materially from the results discussed in the forward-looking statements.

SUMMARY

     Going forward,  Select  Therapeutics  Inc.  ("Select" or the "Company") has
become a  reporting  company  under  federal  securities  laws and has  recently
succeeded in obtaining  the bridge funds it required to position the Company for
a significant  financing and development  partnerships with other companies.  It
has a strong portfolio of product  opportunities in therapeutics for cancer, two
of which have been advanced to the stage at which  clinical  investigations  may
begin  (subject  to  adequate  funding  resources).   Product  sales  at  Sierra
Diagnostics  have  begun and  although  growth of sales  have been  slower  than
expected and do not currently cover operating  costs,  interest in both products
is high and  significant  sales growth is anticipated in 2000. We are adding new
products  and  technology  to Sierra  as part of an  overall  plan to  develop a
diagnostics business with both sales and earnings.

     Research results from key collaborations  continue to be encouraging.  Most
notably the program at the  Institut  Curie,  with  respect to  presentation  of
antigens to dendritic cells, has progressed well and moved significantly towards
clinical  experiments  aimed at  validating  the  potential of this approach for
development of therapeutic vaccines for cancers.

     As noted below,  subsequent  share  placements  have improved the financial
position of Select.  We look forward to  continuing  to develop the potential of
the Company's technology and bringing realizable value to our shareholders.

OVERVIEW

     The Company is a  development  stage  biopharmaceutical  company  formed to
acquire  and  develop  rights  to  selected  early-stage  compounds  which  have
potential use as therapeutics or diagnostics.  Since its inception  (December 6,
1996),  substantially  all of the  Company's  resources  have been  dedicated to
research and development and technology acquisition and management. To date, the
Company has not generated significant product revenue from the sale of Gonostat,
launched  in  January  1999,  and it does not  expect  to  generate  significant
revenues for at least three years while its


                                       7
<PAGE>


other products are under development. The continuation of the Company as a going
concern is dependent on additional  equity  financing and on the  development of
economically  viable  products.  The Company has incurred  losses of $2,467,328,
$1,919,240  and  $199,034  in  fiscal  1999,  1998 and 1997,  respectively,  and
negative cash flow is expected to continue for the Company for at least the next
three  years.  There can be no  assurance  that funding will be available to the
Company  or that the  Company  will be able to develop  an  economically  viable
product.

     The Company expects its sources of revenue,  for the next several years, to
consist principally of sales of diagnostic products and of payments under future
corporate  partnerships.  The process of developing  the  Company's  therapeutic
products  will  require   significant   additional   research  and  development,
preclinical testing and clinical trials, as well as regulatory approvals.  These
activities, together with the Company's general and administrative expenses, are
expected  to result in  operating  losses  for at least  three more  years.  The
Company will not receive  product  revenue from  therapeutic  products unless it
completes  clinical trials and successfully  commercializes  or arranges for the
commercialization of one or more of its products,  as to the success of which no
assurance can be given.

     The  Company  is subject to risks  common to  biopharmaceutical  companies,
including  risks inherent in its research and  development  efforts and clinical
trials,   reliance  on  collaborative   partners,   enforcement  of  patent  and
proprietary  rights,  the need for future  capital,  potential  competition  and
uncertainty of regulatory approval. In order for a product to be commercialized,
it  will  be  necessary  for  the  Company  and  its  collaborators  to  conduct
preclinical  tests and clinical trials,  demonstrate  efficacy and safety of the
Company's  product  candidates,  obtain  regulatory  clearances  and enter  into
manufacturing,  distribution  and  marketing  arrangements  either  directly  or
through  sublicensees.  There can be no assurance that the company will generate
revenues or achieve and sustain profitability in the future.

     During the quarter  which ended Sept 30th,  Select was able to accomplish a
number of key tasks under severely  constrained  financial  circumstances.  Most
important  was the Company's  filing to become a reporting  issuer -a step which
had been  delayed  by a number  of  circumstances  and  which  is  essential  to
obtaining financing for continuing  operations.  The Company entered this period
with a  depleted  treasury  and  expectations  of a  financing  which  were  not
realized.  Management  efforts were directed to completion of the required 10-SB
registration statement (filed on September 16th) and obtaining bridge funds.


                                       8
<PAGE>


     During the quarter,  restricted shares were sold to an unrelated party in a
negotiated  transaction  for $250,000 of which $125,000 was received  during the
quarter.  This  provided  needed  working  capital.   Subsequently,  two  bridge
placements  (one completed and one still  ongoing)  secured  additional  working
capital.   Management  and  key  consultants  deferred  their  compensation  and
significant  accounts payable are outstanding to professional  service providers
and collaborating academic institutions as a result of cash constraints.

     The funding required for the Company to enter clinical trials significantly
exceeds the magnitude of funds raised by the Company to date and there can be no
assurance  that such  funding is  available  on  acceptable  terms if at all. In
December,  the Company  signed a placement  agent  agreement  for a  significant
private  placement  which is planned for the first quarter of calendar  2000. If
successful, this placement will provide an adequate operating base for Select to
move  forward in its  clinical  programs  which have been put on 'hold'  pending
availability of funds for their support.

Program Review.

     During the quarter ended  September  30th, the Company was able to maintain
and  expand  its  research   collaborations  and  strengthen  its  portfolio  of
intellectual  property.  Academic  research on  applications  of Verotoxin  (VT)
continued in collaborating institutions; however, due to the significant funding
requirements, production of clinically qualified materials was not initiated and
all  clinically  oriented  programs  were  halted  for both  purging  and direct
applications  of the  toxin.  Both of these  programs  continue  to be viewed as
promising and management believes that with appropriate  funding,  both can move
forward rapidly since  institutional  collaborations  are in place with clinical
investigators.

     The  application of VT to present  antigens to dendritic cells continues to
be a promising  approach to development  of therapeutic  vaccines for cancer and
other  diseases  which  circumvent the immune  system's  surveillance.  Research
carried out under the Company's  option  agreement  with the Institut  Curie has
resulted in  promising  findings and a plan for  clinical  investigation  of the
technology  is being  developed  in  collaboration  with Dr.  Evan  Hersh at the
Arizona   Cancer  Center.   As  with   chemotherapeutic   applications   of  VT,
significantly increased levels of expenditure will be required as investigations
move  from the  research  laboratory  setting  to the  clinical  setting.  These
expenses   include  but  are  not  limited  to   development  of  materials  and
formulations  which are compliant with regulatory  requirements and the costs of
patient recruitment and monitoring in trial settings.


                                       9
<PAGE>

     Both the purging  program and the dendritic  cell program  involve  ex-vivo
therapies  (i.e.  treatments are carried out on patient  tissues which have been
removed from the patient). A common characteristic of ex-vivo therapies is that,
relative  to  systemic  administration,  they are less  costly  to  investigate.
Select's focus is on identification  of opportunities  which combine low cost of
development  with a strong  proprietary  position and potentially  short time to
market.  While there can be no assurance  that viable  products will result from
the Company's  programs,  they have the potential to yield therapeutic  products
within  time  and  financial  constraints  which  offer  attractive  risk-return
opportunities for development.

     During the past year, Select purchased Sierra Diagnostics Inc., a developer
and manufacturer of diagnostic  products for consideration  comprising stock and
assumption of debts and operating costs. The purchase and subsequent development
of Sierra was  motivated by three  factors;  a need for in-house  capability  to
develop  diagnostic  tests  required for  therapeutic  programs  such as ex-vivo
purging,  a requirement  for a facility to develop and manufacture the Company's
patented HIV diagnostic,  and the desire to develop  earnings from operations in
order to offset development costs.  Sierra has a base of proprietary  technology
relating to assays for  sexually  transmitted  diseases and handling of clinical
samples.  It has launched  two  products in 1999 both of which have  significant
revenue potential.  The first product,  Gonostat,  is a clinical laboratory test
for gonorrhea which offers unique advantages in cost and performance relative to
other  technologies  available  in the  market.  Although  the  market is highly
competitive,  Gonostat is expected to capture a  significant  niche and become a
profitable  product.  The second product brought to market by Sierra is a sample
preservation and handling product which eliminates the need for refrigeration of
clinical  samples  intended for molecular  (DNA/RNA based) assays.  This product
fits into the general  practice of clinical testing and is expected to find wide
application  due to  elimination  of  sample  degradation  and thus the need for
repeat  testing  or  sampling  with  attendant  costs  and  inconvenience.   The
technology is proprietary and believed to be patentable.  Sales and licensing of
the  technology  to third  parties  are  beginning.  There can,  however,  be no
assurance of performance in the market of either of these products.

     Sierra Diagnostics has operated within its expense projections but sales of
Gonostat and DNA-RNA Protect,  while  contributing on a gross margin basis, have
lagged expectations. This resulted in a higher than anticipated cash requirement
for Sierra. We have engaged a sales and marketing group on a consulting basis to
assist  in  developing  the  market  for both  products.  However  to date,  the
operations of Sierra have generated losses and there can be no

                                       10
<PAGE>


assurance that profitable operations will be achieved or that, if achieved, they
can be maintained.

RESULTS OF OPERATIONS

     The Company has been unprofitable from its formation and has an accumulated
deficit  of  $5,118,066  through  September  30,  1999.  For the  quarter  ended
September 30, 1999,  Select incurred a net loss of $532,464 compared with a loss
of $529,472 for the three months ended  September 30, 1998. The decrease in loss
per share  form $0.13 to $0.09  reflects  the  increase  in the number of common
shares. The net loss is a result of the routine operations of the Company in its
development  stage.  We expect  losses to  continue  and  increase  for the next
several years as the Company pursues  development and  commercialization  of its
intellectual property resources.

     During the quarter the Company's  cash position  decreased from $120,881 to
$44,980,  and there was an increase in accounts payable and accrued  liabilities
from  $699,107  to  $924,962.  Cash and cash  equivalents  for the period  ended
September 30, 1999 were $44,980 versus $1,386,333 for the period ended September
30,  1998.  Payments  to certain  members of  management  and  consultants  were
suspended or reduced during this period.  Cash raised from the private placement
of securities  subsequent to the period has considerably  improved the prospects
for  the  Company  and  management  is  optimistic  that  adequate  funding  for
continuation  of operations and development of the Company's  technology  assets
can be obtained.

Revenues.

     Revenues  of $93,631  during the  quarter  ended  September  30,  1999 were
principally from the sale of Gonostat; interest income for the quarter was $506.
During the corresponding  quarter in 1998, there were no revenues from sales and
interest income was $14,908. Select's sole operating revenues to date arise from
sales of  diagnostic  products  through  its  wholly  owned  subsidiary,  Sierra
Diagnostics.  The Company has no other product or license  revenues.  Management
anticipates  that future revenues may consist  primarily of product sales either
directly by the Company or, more likely,  through collaborative  development and
marketing  agreements  with  other  companies  in the  pharmaceutical  industry.
Although  Sierra's  operations are expected to achieve  breakeven  during fiscal
2000  and  thereafter  be  profitable,  there  can  be no  assurance  that  such
performance will be realized or maintained.


                                       11
<PAGE>


Costs and Expenses.

     Operating   expenses  for  the  quarter  ended   September  30,  1999  were
significantly  reduced  compared  to the  same  period  in  1998;  however,  the
reduction was required by the Company's  severely  limited cash  resources.  The
Company has to defer expenditures required to advance its development projects.

     All  research  and  development  activities  of the  Company and its patent
costs, are expensed as incurred.  Personnel costs including retained consultants
and external  contractors are the largest  ongoing cost of operations.  Locating
and  retaining  appropriate  personnel  resources  is a priority and the Company
anticipates  that personnel costs will increase if adequate funding is obtained.
The Company has no long term employment contracts or liabilities for severances.
At June 30, 1999 the Company employed seven people, mainly at Sierra Diagnostics
and retained  services of three key  consultants who are an integral part of the
Company management.

Capital Expenditures.

         There were no significant capital expenditures during the quarter.

LIQUIDITY AND CAPITAL RESOURCES

     The Company has financed its operations since inception  primarily  through
private placements of its Common Stock. As of September 30, 1999 the Company had
received  approximately  $3,417,297  in net  proceeds  from the  sale of  equity
securities.

     Cash at June 30, 1999 totaled $120,881.  In the quarter ended September 30,
1999 the Company  received  $125,000  from the private sale of 50,000  shares of
restricted common stock. Subsequently, it also received $857,700 from additional
securities sales.

     The Company's limited financial resources have forced it to curtail some of
its planned  operations  through 1999, and the Company will require  substantial
additional funding in order to complete its research and development  activities
and sublicense any potential products. The Company's future capital requirements
will depend on many factors,  including  scientific progress in its research and
development  programs,  the size and complexity of such programs,  the scope and
results of preclinical  studies and clinical trials,  the ability of the Company
to establish and maintain corporate partnerships, the time and costs involved in
obtaining regulatory  approvals,  the costs involved in filing,  prosecuting and
enforcing patent claims,  competing  technological and market developments,  the
cost of manufacturing preclinical and clinical


                                       12
<PAGE>


material and other  factors not within the  Company's  control.  There can be no
assurance that the additional  financing  necessary to meet the Company's  short
and long-term  capital  requirements will be available on acceptable terms or at
all.

     Insufficient  funds  may  require  the  Company  to  delay,  scale  back or
eliminate  some or all of its research or development  programs,  to lose rights
under  existing  licenses  or to  relinquish  greater  or all  rights to product
candidates at an earlier stage of development  or on less  favorable  terms than
the Company would otherwise choose or may cause the Company to cease operations.
If  additional  funds  are  raised by  issuing  equity  securities,  substantial
dilution to existing stockholders likely will result.

     Sales of Sierra's  products to date are not  sufficient to cover  operating
costs.  The Company  currently has funds  sufficient to continue  operations for
less than three months and does not have funds required to move current projects
into clinical investigations.  In December, the Company signed a placement agent
agreement for a  significant  private  placement  which is planned for the first
quarter of calendar 2000. If successful, this placement will provide an adequate
operating  base for Select to move forward in its clinical  programs  which have
been put on 'hold' pending  availability of funds for their support.  Management
has been in discussions with a number of parties regarding  additional financing
required  to  maintain  and  develop  the  Company's  position  and  while it is
optimistic that such funds may be available there is no assurance that this will
be the case.

Year 2000.

     Year 2000 (Y2K) issues arise because many  computer  systems use two rather
than  four  digits to  identify  the year thus  creating  ambiguities  which may
produce  errors before,  on or after January 1, 2000. If not  addressed,  errors
could impact all aspects of operations including financial  reporting,  clinical
and  production  records or controls and  communications.  Errors may range from
minor to  significant  systems  failures and could be imported  from  suppliers'
systems.

     We have  assessed,  taken  corrective  actions in light of, and continue to
monitor our vulnerability to Y2K issues in all aspects of our business including
information and computer systems and critical  suppliers and service  providers.
To the best of our knowledge,  systems and equipment  critical to our operations
are Y2K compliant; however, it is not possible to be certain that the systems of
our suppliers,  service  providers or other third parties upon which we rely are
compliant or that they will  unaffected  by problems in their own supply  chain.
Based on the nature of our


                                       13
<PAGE>


operations  and ongoing  assessments  we believe  that Select has little  direct
exposure to Y2K issues.

     We estimate that our direct costs of addressing the Y2K issue are less than
$5,000,  which  are  being  expensed  in  the  normal  course  of  our  business
operations.

ITEM 6.  Exhibits and Reports on Form 8-K

     (a)  Exhibits

     The following exhibit is filed with this report:                      Page

     27.  Financial Data Schedule                                           16


                                       14
<PAGE>


                                   SIGNATURES


     In accordance  with the  requirements  of the Exchange Act, the  registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


Dated: January 11, 2000                        SELECT THERAPEUTICS, INC.



                                               By: /s/ Robert Bender
                                                   -----------------------------
                                                   Name: Robert Bender
                                                   Title: Chairman of the Board



                                       15